GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kymera Therapeutics Inc (NAS:KYMR) » Definitions » Total Current Liabilities

Kymera Therapeutics (Kymera Therapeutics) Total Current Liabilities : $56.14 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kymera Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Kymera Therapeutics's total current liabilities for the quarter that ended in Mar. 2024 was $56.14

Kymera Therapeutics Total Current Liabilities Historical Data

The historical data trend for Kymera Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kymera Therapeutics Total Current Liabilities Chart

Kymera Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial 34.57 110.62 92.54 71.34 85.69

Kymera Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.93 54.60 63.17 85.69 56.14

Kymera Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Kymera Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=40.939+6.345
+Other Current Liabilities+Current Deferred Liabilities
=0.524+37.883
=85.69

Kymera Therapeutics's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=22.809+9.89
+Other Current Liabilities+Current Deferred Liabilities
=0.82400000000001+22.613
=56.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Kymera Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Kymera Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kymera Therapeutics (Kymera Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kymera Therapeutics Inc (NAS:KYMR) » Definitions » Total Current Liabilities
Comparable Companies
AMAM ADPT RGNX INBX KURA VERV AKRO IMTX NAMS NVAX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
200 Arsenal Yards Boulevard, Suite 230, Watertown, MA, USA, 02472
Website
https://www.kymeratx.com
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Executives
Jeffrey W. Albers director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Ellen Chiniara officer: Chief Legal Officer 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jeremy G Chadwick officer: Chief Operating Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
Bruce N. Jacobs officer: Chief Financial Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451
Atlas Venture Fund X, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Leigh Morgan director KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
John Maraganore director 75 SIDNEY ST, CAMBRIDGE MA 02139
Nello Mainolfi director, officer: President and CEO C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Jared Gollob officer: Chief Medical Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Richard Chesworth officer: Chief Scientific Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Atlas Venture Associates X, L.p. 10 percent owner 400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Elaine Caughey officer: Chief Business Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472

Kymera Therapeutics (Kymera Therapeutics) Headlines

From GuruFocus

Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma

By Marketwired • 09-18-2023

Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

By sperokesalga sperokesalga • 06-09-2023

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

By sperokesalga sperokesalga • 05-18-2023

Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

By sperokesalga sperokesalga • 05-22-2023

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

By Marketwired • 08-28-2023

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

By Marketwired • 10-16-2023

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and�Provides a Business Update

By Marketwired • 11-02-2023

Director Jeffrey Albers Sells 10,000 Shares of Kymera Therapeutics Inc

By GuruFocus Research • 01-24-2024

Kymera Therapeutics' STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

By sperokesalga sperokesalga • 06-14-2023

Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3

By Marketwired • 07-27-2023